Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data

Thierry Wendling*, Hitesh Mistry, Kayode Ogungbenro, Leon Aarons

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
23 Downloads (Pure)


Purpose Measures derived from longitudinal tumour size data have been increasingly utilised to predict survival of patients with solid tumours. The aim of this study was to examine the prognostic value of such measures for patients with metastatic pancreatic cancer undergoing gemcitabine therapy. Methods The control data from two Phase III studies were retrospectively used to develop (271 patients) and validate (398 patients) survival models. Firstly, 31 baseline variables were screened from the training set using penalised Cox regression. Secondly, tumour shrinkage metrics were interpolated for each patient by hierarchical modelling of the tumour size time-series. Subsequently, survival models were built by applying two approaches: the first aimed at incorporating model-derived tumour size metrics in a parametric model, and the second simply aimed at identifying empirical factors using Cox regression. Finally, the performance of the models in predicting patient survival was evaluated on the validation set. Results Depending on the modelling approach applied, albumin, body surface area, neutrophil, baseline tumour size and tumour shrinkage measures were identified as potential prognostic factors. The distributional assumption on survival times appeared to affect the identification of risk factors but not the ability to describe the training data. The two survival modelling approaches performed similarly in predicting the validation data. Conclusions A parametric model that incorporates model-derived tumour shrinkage metrics in addition to other baseline variables could predict reasonably well survival of patients with metastatic pancreatic cancer. However, the predictive performance was not significantly better than a simple Cox model that incorporates only baseline characteristics.

Original languageEnglish
Pages (from-to)927-938
Number of pages12
JournalCancer Chemotherapy and Pharmacology
Issue number5
Publication statusPublished - 3 Mar 2016
Externally publishedYes

Bibliographical note

Copyright the Author(s) 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


Dive into the research topics of 'Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data'. Together they form a unique fingerprint.

Cite this